Moreover, two signatures for assessing the ability to release IFN-γ, IFNG, and Merck18 both suggest that the patients of the low-MRGPI subgroup have a stronger IFN-γ release ability, which indirectly reflects that they have a stronger tumor-killing effect (Figures 5C, D). This evidence concerns the gene IFNG and neoplasm.